PL371056A1 - Kompozycja farmaceutyczna inhibitora PDE4 i PDE3/4 i receptora histaminy - Google Patents

Kompozycja farmaceutyczna inhibitora PDE4 i PDE3/4 i receptora histaminy

Info

Publication number
PL371056A1
PL371056A1 PL03371056A PL37105603A PL371056A1 PL 371056 A1 PL371056 A1 PL 371056A1 PL 03371056 A PL03371056 A PL 03371056A PL 37105603 A PL37105603 A PL 37105603A PL 371056 A1 PL371056 A1 PL 371056A1
Authority
PL
Poland
Prior art keywords
pde3
pde4
inhibitor
pharmaceutical composition
receptor antagonist
Prior art date
Application number
PL03371056A
Other languages
English (en)
Other versions
PL211574B1 (pl
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PL371056A1 publication Critical patent/PL371056A1/pl
Publication of PL211574B1 publication Critical patent/PL211574B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL371056A 2002-03-06 2003-02-25 Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego PL211574B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06

Publications (2)

Publication Number Publication Date
PL371056A1 true PL371056A1 (pl) 2005-06-13
PL211574B1 PL211574B1 (pl) 2012-05-31

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371056A PL211574B1 (pl) 2002-03-06 2003-02-25 Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego

Country Status (31)

Country Link
US (1) US20050112069A1 (pl)
EP (2) EP1849468B1 (pl)
JP (1) JP5150034B2 (pl)
KR (1) KR20040095255A (pl)
CN (1) CN101257904A (pl)
AR (1) AR038858A1 (pl)
AT (1) ATE369134T1 (pl)
AU (1) AU2003212268B2 (pl)
BR (1) BR0308220A (pl)
CA (1) CA2478612C (pl)
CO (1) CO5611148A2 (pl)
CY (2) CY1106927T1 (pl)
DE (1) DE60315426T2 (pl)
DK (2) DK1482938T3 (pl)
EA (2) EA010886B1 (pl)
ES (2) ES2400670T3 (pl)
HR (1) HRP20040909B1 (pl)
IL (1) IL163336A (pl)
IS (2) IS2536B (pl)
MX (1) MXPA04008460A (pl)
NO (1) NO335254B1 (pl)
NZ (1) NZ535611A (pl)
PL (1) PL211574B1 (pl)
PT (2) PT1482938E (pl)
RS (1) RS51018B (pl)
SG (1) SG160197A1 (pl)
SI (2) SI1849468T1 (pl)
TW (1) TWI347845B (pl)
UA (1) UA80117C2 (pl)
WO (1) WO2003074055A1 (pl)
ZA (1) ZA200407104B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
WO2009067597A1 (en) * 2007-11-21 2009-05-28 Decode Genetics Ehf 4- (or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
RS55624B1 (sr) 2011-02-07 2017-06-30 Scipharm Sàrl Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CN106604747A (zh) * 2014-08-26 2017-04-26 基础应用医学研究基金会 用于治疗和预防伴随认知缺陷或缺损的神经障碍以及神经变性疾病的产品
NZ731344A (en) 2014-10-09 2018-08-31 Guangdong Raynovent Biotech Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
AU781137B2 (en) * 1999-10-25 2005-05-05 Altana Pharma Ag Tetrahydrothiopy ranphthalazinone derivatives as PDE4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
SI1482938T1 (sl) 2007-12-31
RS78004A (sr) 2006-12-15
DK1482938T3 (da) 2007-12-03
AU2003212268A1 (en) 2003-09-16
EP1482938B1 (en) 2007-08-08
EA200401137A1 (ru) 2005-04-28
ATE369134T1 (de) 2007-08-15
EP1849468B1 (en) 2012-12-05
PT1849468E (pt) 2013-02-27
EA007903B1 (ru) 2007-02-27
HK1071308A1 (en) 2005-07-15
EP1482938A1 (en) 2004-12-08
CA2478612A1 (en) 2003-09-12
IS2536B (is) 2009-08-15
WO2003074055A1 (en) 2003-09-12
SI1849468T1 (sl) 2013-03-29
ES2400670T3 (es) 2013-04-11
DE60315426T2 (de) 2008-07-03
JP5150034B2 (ja) 2013-02-20
AU2003212268B2 (en) 2008-09-11
CO5611148A2 (es) 2006-02-28
ES2291618T3 (es) 2008-03-01
UA80117C2 (uk) 2007-08-27
AR038858A1 (es) 2005-01-26
PT1482938E (pt) 2007-11-15
CY1113894T1 (el) 2016-07-27
CN101257904A (zh) 2008-09-03
EA200601592A1 (ru) 2006-12-29
EP1849468A2 (en) 2007-10-31
JP2005524666A (ja) 2005-08-18
IS8760A (is) 2008-09-04
HRP20040909A2 (en) 2005-08-31
US20050112069A1 (en) 2005-05-26
SG160197A1 (en) 2010-04-29
HRP20040909B1 (en) 2012-11-30
NZ535611A (en) 2006-03-31
NO335254B1 (no) 2014-10-27
DE60315426D1 (de) 2007-09-20
EA010886B1 (ru) 2008-12-30
DK1849468T3 (da) 2013-02-04
CA2478612C (en) 2013-12-10
KR20040095255A (ko) 2004-11-12
BR0308220A (pt) 2005-01-04
MXPA04008460A (es) 2004-12-06
RS51018B (sr) 2010-10-31
IS7438A (is) 2004-09-03
CY1106927T1 (el) 2012-09-26
IL163336A (en) 2009-02-11
NO20044230L (no) 2004-12-06
TW200306855A (en) 2003-12-01
TWI347845B (en) 2011-09-01
EP1849468A3 (en) 2007-11-07
PL211574B1 (pl) 2012-05-31
ZA200407104B (en) 2006-12-27

Similar Documents

Publication Publication Date Title
IS8760A (is) Lyfjablanda úr pde4 eða pde3/4 tálma og histamínviðtakamótlyfi
IL159588A0 (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
HUP0302615A3 (en) Kinase inhibitor quinazoline derivatives and pharmaceutical compositions containing them and their use
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
PL374878A1 (pl) Zastosowanie inhibitorów CETP i ewentualnie inhibitorów reduktazy HMG CoA i/lub środków przeciw nadciśnieniu
HUP0400475A3 (en) Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
AU2002231570A1 (en) Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
IL153645A0 (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor
IL205407A0 (en) Hyaluronic acid antagonist and inhibitor compositions and uses thereof
IL159538A0 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
AU2002227123A1 (en) Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
HUP0500078A3 (en) Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
PL369736A1 (pl) Nowe kompozycje leków na bazie antycholinergików oraz inhibitorów kinazy EGFR
AU2003206014A8 (en) Neuropeptide receptor and uses thereof
IL148292A0 (en) Pharmaceutical compositions of halofuginone and other quinazolinone derivatives
AU2003231019A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING Alpha3Beta4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE
AU2003247052A1 (en) Mcp-1 receptor antagonists and method of use thereof
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use
AU2002339817A1 (en) Use of inhibitors of the y2 receptor of neuropeptide y in the treatment of alcoholism
HK1057541A (en) Carboxamide compounds and their use as antagonists of a human 11cby receptor
AU2002354760A1 (en) Glucocorticoid-induced receptor and methods of use
AU2002322290A1 (en) Vitamin d receptor antagonists and related compositions and methods of use
HK1062435A (en) Antagonists of mcp-1 function and methods of use thereof